8-K: Cerus Corp Q2 2026 Results: Revenue Up, Guidance Raised

Cerus Corporation reported a 10% year-over-year increase in product revenue to $57.4 million for the second quarter of 2026, and raised the lower end of its full-year product revenue guidance.

Summary

• Cerus Corporation announced its financial results for the second quarter ended June 30, 2026.
• Total revenue for the quarter was $63.3 million, a 5% increase year-over-year.
• Product revenue reached $57.4 million, up 10% year-over-year, driven by growth across all product categories.
• Government contract revenue decreased by 24% to $5.9 million.
• The company raised its full-year 2026 product revenue guidance to a range of $229 million to $231 million, an 11% to 12% increase from 2025.
• Full-year 2026 INTERCEPT Fibrinogen Complex (IFC) sales outlook was also raised to $23 million to $25 million, an approximate 40% to 50% year-over-year increase.
• Second-quarter net loss attributable to Cerus Corporation was $2.9 million ($0.01 per share), an improvement from a net loss of $5.7 million ($0.03 per share) in the prior year period.
• Non-GAAP Adjusted EBITDA was positive $3.0 million for the second quarter of 2026, compared to positive $0.9 million in the prior year period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with revenue growth exceeding expectations and guidance being raised. The improvement in net loss and positive adjusted EBITDA are also encouraging signs, despite some margin pressures.

Positives

• Product revenue increased by 10% year-over-year to $57.4 million in Q2 2026.
• Total revenue grew 5% year-over-year to $63.3 million in Q2 2026.
• The company raised its full-year 2026 product revenue guidance to $229 million $231 million.
• The full-year 2026 IFC sales outlook was raised to $23 million $25 million, representing 40%-50% Y/Y growth.
• Second-quarter net loss improved to $2.9 million from $5.7 million in the prior year.
• Non-GAAP Adjusted EBITDA turned positive at $3.0 million for Q2 2026, up from $0.9 million in Q2 2025.
• Demand for IFC increased approximately 20% in Q2 2026 compared to the prior year.
• Completed debt refinancing, reducing the outstanding term loan by $30 million.

Negatives

• Government contract revenue decreased by 24% to $5.9 million in Q2 2026.
• Product gross margin decreased to 51.4% in Q2 2026 from 55.2% in Q2 2025, primarily due to a weaker U.S. dollar and higher product costs.
• Cash, cash equivalents, and short-term investments decreased to $56.3 million at June 30, 2026, from $82.9 million at December 31, 2025.
• Cash used in operations increased to $2.7 million in Q2 2026 from $2.4 million in Q2 2025, tied to an increase in working capital.

Risks

• Risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System and IFC.
• The risk that Cerus may not meet its 2026 annual product revenue guidance.
• The risk that Cerus may not effectively continue to launch and commercialize the INTERCEPT Blood System for Cryoprecipitation or INT200.
• Risks related to the uncertain and time-consuming development and regulatory process, including obtaining regulatory approvals.
• Macroeconomic developments such as inflation, rising interest rates, and foreign exchange volatility could disrupt global economic and financial conditions.
• Risks associated with Cerus ability to maintain an effective, secure manufacturing supply chain.
• Risks associated with Cerus ability to access additional funds under its credit facility and to meet its debt service obligations, and its need for additional funding.
• Risks associated with the impact of legislative or regulatory healthcare reforms.

Future Outlook

The company raised its full-year 2026 product revenue guidance to a range of $229 million to $231 million, representing 11% to 12% growth from 2025. The IFC revenue guidance was also increased to $23 million to $25 million. Key anticipated catalysts in 2026 include ongoing INTERCEPT RBC regulatory review in Europe, Phase 3 RedeS readout in the U.S., and the U.S. PMA submission for the INT200 illumination device.

Management Comments

• "This quarter we made significant progress in expanding patient access to safer blood components around the globe," said Vivek Jayaraman, Cerus president and chief executive officer.
• "I'm particularly pleased with the performance of our INTERCEPT Fibrinogen Complex (IFC) franchise in the U.S. The value proposition for blood centers, hospitals and clinicians is resonating and leading to earlier patient access to fibrinogen across the country. We view IFC as a compelling growth driver for Cerus."

Industry Context

StockSavvy.ai notes that Cerus Corporation's results reflect a growing demand for pathogen reduction technologies in the blood supply chain, driven by increasing awareness of transfusion-transmitted infections and the need for enhanced blood safety. The company's focus on expanding patient access globally and its strategic partnerships, such as with BARDA, position it within a critical segment of the healthcare industry.

Comparison to Industry Standards

• No direct industry standard comparables or benchmarks were provided in the filing for direct comparison of Q2 2026 financial metrics.
• The company's product revenue growth of 10% in Q2 2026 and raised full-year guidance of 11%-12% suggests performance potentially above the average growth rate for medical device companies, though specific industry benchmarks are not detailed.
• The improvement in net loss and positive Non-GAAP Adjusted EBITDA are positive indicators, but without specific industry peer data in the filing, a direct comparison is not possible.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth, raised guidance, and improved financial metrics, though margin pressures and cash burn remain factors.
• Customers (Blood Centers, Hospitals): Continued access to and potential expansion of safer blood components through INTERCEPT technologies.
• Suppliers: Continued demand for components and services to support manufacturing and product development.
• Creditors: Improved financial performance may positively impact the company's ability to service its debt obligations.

Next Steps

• Anticipate a regulatory decision for the INTERCEPT Blood System for Platelets with INT200 Illuminator in early 2027.
• Continue to advance the development of the INTERCEPT Red Blood Cell system through the expanded BARDA collaboration.
• Host a conference call on July 30, 2026, to discuss financial results and provide a business overview and outlook.

Key Dates

Recommendation

The company is showing positive revenue momentum and has raised its guidance, which is encouraging. However, persistent net losses, declining gross margins, and a significant decrease in cash reserves warrant a cautious approach. While the improvements are notable, the path to sustained profitability and the impact of ongoing risks require further observation before a stronger buy recommendation can be made.

Keywords

INTERCEPT Blood System, Fibrinogen Complex, Pathogen Reduction, Blood Safety, Medical Devices, Revenue Growth, Financial Results, Biotechnology